MedTrace Logo

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

NCT05764590 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2024-01-10

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus:

* How much effect AP-306 has assessed by blood phosphorus lowering;
* How safe and tolerable AP-306 is.

Participants will receive either following treatments:

* AP-306, and
* Sevelamer carbonate.

Conditions

  • Chronic Kidney Diseases
  • Hyperphosphatemia

Interventions

DRUG

AP-306

A blood phosphorus lowering drug with a novel mechanism

DRUG

Sevelamer Carbonate

A phosphate binder

Sponsors & Collaborators

  • Alebund Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Li Wang, MD · Sichuan Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2023-08-25
Completion
2023-09-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764590 on ClinicalTrials.gov